CA2334761C - Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes - Google Patents
Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes Download PDFInfo
- Publication number
- CA2334761C CA2334761C CA002334761A CA2334761A CA2334761C CA 2334761 C CA2334761 C CA 2334761C CA 002334761 A CA002334761 A CA 002334761A CA 2334761 A CA2334761 A CA 2334761A CA 2334761 C CA2334761 C CA 2334761C
- Authority
- CA
- Canada
- Prior art keywords
- hmb
- composition
- arginine
- animal
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
L'invention concerne une composition comprenant de l'acide beta -hydroxy- beta -méthylbutyrique (HMB) et au moins un amino-acide. La présente invention concerne également une méthode de traitement de la fonte musculaire d'un animal liée à la maladie, une méthode permettant de réduire le taux sérique des triglycérides d'un animal, une méthode de réduction de la charge virale sérique d'un animal, une méthode de redistribution des graisses dans un animal ayant une zone viscérale et un zone sous-cutanée, une méthode permettant d'accroître la masse maigre d'un animal sans réduction sensible de sa masse adipeuse, et une méthode permettant d'accroître le niveau de cholestérol HDL chez un animal. Toutes ces méthodes impliquent l'administration d'une composition comprenant de l'acide beta -hydroxy- beta -méthylbutyrique et au moins un amino-acide à l'animal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/102,941 | 1998-06-23 | ||
US09/102,941 US6031000A (en) | 1998-06-23 | 1998-06-23 | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
PCT/US1999/014097 WO1999066917A2 (fr) | 1998-06-23 | 1999-06-23 | COMPOSITION COMPRENANT DE L'ACIDE β-HYDROXY-β-METHYLBUTYRIQUE ET AU MOINS UN AMINO-ACIDE, ET METHODES D'UTILISATION CORRESPONDANTES |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2334761A1 CA2334761A1 (fr) | 1999-12-29 |
CA2334761C true CA2334761C (fr) | 2009-04-28 |
Family
ID=22292520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002334761A Expired - Lifetime CA2334761C (fr) | 1998-06-23 | 1999-06-23 | Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes |
Country Status (12)
Country | Link |
---|---|
US (1) | US6031000A (fr) |
EP (1) | EP1089726B1 (fr) |
JP (2) | JP5064609B2 (fr) |
AU (1) | AU756353B2 (fr) |
CA (1) | CA2334761C (fr) |
DE (1) | DE69901396T2 (fr) |
DK (1) | DK1089726T3 (fr) |
ES (1) | ES2177293T3 (fr) |
NO (2) | NO329914B1 (fr) |
NZ (1) | NZ508395A (fr) |
PL (1) | PL195623B1 (fr) |
WO (1) | WO1999066917A2 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3362350B2 (ja) * | 1997-10-16 | 2003-01-07 | 味の素株式会社 | 反芻動物の肥育方法 |
US20040220266A1 (en) * | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US6812249B2 (en) * | 2003-03-04 | 2004-11-02 | Sal Abraham | Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use |
US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
EP1973426A2 (fr) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions visant a prevenir et reduire les courbatures du lendemain |
BRPI0619179A2 (pt) * | 2005-11-30 | 2011-09-13 | Nestec Sa | métodos para o tratamento de perda muscular |
NZ568611A (en) | 2005-12-19 | 2011-11-25 | Abbott Lab | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
US7754693B2 (en) * | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
US8324175B2 (en) | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9770424B2 (en) * | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9539224B2 (en) * | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
DK2381784T3 (en) | 2008-12-09 | 2018-10-22 | Metabolic Tech Inc | Nutritional intervention to improve muscle function and strength |
CA2750944C (fr) * | 2009-01-29 | 2019-01-08 | Young Hee Ko | Compositions et procedes pour le traitement du cancer |
EP2289555A1 (fr) * | 2009-08-24 | 2011-03-02 | OrgaNext Research B.V. | Procédé de traitement des faiblesses |
JP6077857B2 (ja) * | 2009-12-18 | 2017-02-08 | メタボリック・テクノロジーズ,インコーポレーテッド | β−ヒドロキシ−β−メチル酪酸塩(HMB)の改善された投与方法 |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
AU2011210682A1 (en) | 2010-01-29 | 2012-07-05 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
AU2011210691A1 (en) | 2010-01-29 | 2012-07-12 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
JP6158801B2 (ja) | 2011-07-15 | 2017-07-05 | ニューサート サイエンシーズ, インコーポレイテッド | 代謝経路を変調させるための組成物および方法 |
WO2013067485A1 (fr) | 2011-11-03 | 2013-05-10 | University Of Florida Research Foundation, Inc. | Supplément nutritionnel pour la gestion du poids |
US20130143968A1 (en) * | 2011-11-21 | 2013-06-06 | Emmaus Medical, Inc. | Methods and compositions for the treatment of diabetes and related symtoms |
WO2013106570A1 (fr) | 2012-01-11 | 2013-07-18 | Abbott Laboratories | Combinaison de bêta-hydroxy-bêta-méthylbutryate, d'arginine et de glutamine utilisée dans le traitement des ulcères diabétiques |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
PL3733171T3 (pl) | 2012-09-10 | 2024-03-18 | Metabolic Technologies, LLC | Kompozycje zawierające hmb i atp oraz ich zastosowanie |
JP6346896B2 (ja) | 2012-09-21 | 2018-06-20 | アボット・ラボラトリーズAbbott Laboratories | カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物 |
WO2014047493A1 (fr) * | 2012-09-21 | 2014-03-27 | Abbott Laboratories | Compositions nutritionnelles comprenant le bêta-hydroxy-bêta-méthylbutyrate de calcium et une protéine |
SG10201709195TA (en) | 2012-11-13 | 2017-12-28 | Nusirt Sciences Inc | Compositions and methods for increasing energy metabolism |
MX2015012821A (es) * | 2013-03-14 | 2016-05-31 | Abbott Lab | Tratamiento de resistencia a la insulina asociado con la inactividad fisica prolongada. |
CA2902879C (fr) | 2013-03-15 | 2023-09-26 | Nusirt Sciences, Inc. | Leucine et acide nicotinique reduisant les taux de lipides |
US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
CN106456997B (zh) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | 用于减少或预防肝性脂肪变性的组合物和方法 |
EP3302704B1 (fr) * | 2015-06-01 | 2023-01-25 | Metabolic Technologies, Inc. | Compositions et procédés d'utilisation de bêta-hydroxy-bêta-méthylbutyrate (hmb) pour la diminution de la masse graisseuse |
WO2017049093A1 (fr) | 2015-09-16 | 2017-03-23 | Metabolic Technologies, Inc. | Compositions et procédés d'utilisation de butyrate de ss-hydroxy-ss-méthyle (hmb) pour améliorer la récupération après un traumatisme d'un tissu mou |
JP6875288B2 (ja) * | 2015-11-19 | 2021-05-19 | 協和発酵バイオ株式会社 | 3−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法 |
BR122023026038A2 (pt) | 2016-01-21 | 2024-01-16 | Metabolic Technologies, Inc. | Usos de um ácido e de um modulador de autofagia e de lipofagia |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
WO2017184788A1 (fr) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration de butyrate, de bêta-hydroxybutyrate et de composés apparentés à des humains |
CN109476578A (zh) | 2016-06-24 | 2019-03-15 | 协和发酵生化株式会社 | 3-羟基异戊酸氨基酸盐的晶体及其制造方法 |
CN110167544A (zh) | 2016-10-21 | 2019-08-23 | 代谢科技有限公司 | β-羟基-β-甲基丁酸(HMB)和益生菌的组合物及使用方法 |
JOP20190146A1 (ar) * | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
KR20200131810A (ko) * | 2018-01-05 | 2020-11-24 | 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 | 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법 |
EP3810123A1 (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157022A (en) * | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
ES2142353T3 (es) * | 1992-09-16 | 2000-04-16 | Univ Iowa State Res Found Inc | Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. |
US5348979A (en) * | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
AU6102994A (en) * | 1993-02-11 | 1994-08-29 | Iowa State University Research Foundation Inc. | Method of enhancing nutritional value of colostrum and first milk of pregnant mammals |
US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US5756469A (en) * | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
DE29707308U1 (de) * | 1997-04-23 | 1997-06-26 | Kunz, Armin, 66450 Bexbach | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
-
1998
- 1998-06-23 US US09/102,941 patent/US6031000A/en not_active Expired - Lifetime
-
1999
- 1999-06-23 JP JP2000555603A patent/JP5064609B2/ja not_active Expired - Lifetime
- 1999-06-23 WO PCT/US1999/014097 patent/WO1999066917A2/fr active IP Right Grant
- 1999-06-23 DE DE69901396T patent/DE69901396T2/de not_active Expired - Lifetime
- 1999-06-23 CA CA002334761A patent/CA2334761C/fr not_active Expired - Lifetime
- 1999-06-23 DK DK99930567T patent/DK1089726T3/da active
- 1999-06-23 AU AU47080/99A patent/AU756353B2/en not_active Expired
- 1999-06-23 EP EP99930567A patent/EP1089726B1/fr not_active Expired - Lifetime
- 1999-06-23 PL PL99344589A patent/PL195623B1/pl unknown
- 1999-06-23 NZ NZ508395A patent/NZ508395A/en not_active IP Right Cessation
- 1999-06-23 ES ES99930567T patent/ES2177293T3/es not_active Expired - Lifetime
-
2000
- 2000-12-22 NO NO20006633A patent/NO329914B1/no not_active IP Right Cessation
-
2010
- 2010-10-18 NO NO20101440A patent/NO332374B1/no not_active IP Right Cessation
-
2011
- 2011-12-26 JP JP2011282771A patent/JP5690261B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1999066917A3 (fr) | 2000-04-20 |
WO1999066917A2 (fr) | 1999-12-29 |
JP2012102118A (ja) | 2012-05-31 |
NZ508395A (en) | 2003-09-26 |
EP1089726A2 (fr) | 2001-04-11 |
NO329914B1 (no) | 2011-01-24 |
PL195623B1 (pl) | 2007-10-31 |
JP5064609B2 (ja) | 2012-10-31 |
PL344589A1 (en) | 2001-11-05 |
NO20101440L (no) | 2001-02-20 |
AU756353B2 (en) | 2003-01-09 |
US6031000A (en) | 2000-02-29 |
ES2177293T3 (es) | 2002-12-01 |
NO332374B1 (no) | 2012-09-10 |
JP2002518440A (ja) | 2002-06-25 |
EP1089726B1 (fr) | 2002-05-02 |
NO20006633L (no) | 2001-02-20 |
JP5690261B2 (ja) | 2015-03-25 |
DE69901396D1 (de) | 2002-06-06 |
DK1089726T3 (da) | 2002-07-22 |
DE69901396T2 (de) | 2002-08-29 |
NO20006633D0 (no) | 2000-12-22 |
AU4708099A (en) | 2000-01-10 |
CA2334761A1 (fr) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2334761C (fr) | Composition comprenant de l'acide .beta.-hydroxy-.beta.-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes | |
EP2512236B1 (fr) | Procédé amélioré permettant d'administrer du bêta-hydroxy-bêta-méthylbutyrate (hmb) | |
AU664511B2 (en) | Method of promoting nitrogen retention in humans | |
US5453282A (en) | Dietary lipid digestion-absorption inhibitory agents and ingesta | |
RU2195934C2 (ru) | Высокие дозы трипиколината хрома для лечения диабета второго типа | |
JP2008534599A (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
US5431925A (en) | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | |
KR20050089857A (ko) | 간암 발생 및 진행 억제제 | |
EP0786993B1 (fr) | Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et leur utilisation dans le traitement de troubles metaboliques et cardiovasculaires | |
JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
JP3908513B2 (ja) | 肝機能改善剤 | |
KR100304312B1 (ko) | 아연이보충된전립선추출물 | |
EP4331583A1 (fr) | Agent augmentant la carnitine sanguine | |
MXPA00011686A (es) | Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso | |
CN114177185B (zh) | 一种用于降低胆固醇与预防心血管疾病的药物组合物 | |
CA3218375A1 (fr) | Composition pour augmenter la masse musculaire | |
WO1996011679A1 (fr) | Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires | |
JP2001316272A (ja) | 高尿酸血症又は痛風の予防又は改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDC | Discontinued application reinstated | ||
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20190625 |